Hypoxia Tracer Gets FDA Breakthrough Status in HPV+ Oropharyngeal Cancer

The FDA has granted breakthrough therapy designation to fluoromisonidazole F 18 (JBS-003; F-MISO), a hypoxia tracer in development to guide de-escalated radiation therapy in patients with human papillomavirus (HPV)-positive oropharyngeal carcinoma (OPC).¹

The FDA awards breakthrough therapy designation to investigational products addressing serious conditions when early clinical data suggest the therapy could meaningfully outperform existing treatment options on a clinically significant end point. The designation applies to the use of JBS-003 to select patients who may be eligible for a substantially reduced radiation dose based on the absence of tumor hypoxia.

"This designation is a powerful validation of what precision imaging can do for these patients. Using F-MISO PET imaging, we can visualize the specific hypoxic signatures of a tumor to maintain aggressive control where it's needed, while safely reducing radiation doses for patients with well-oxygenated tissue,” Alex Agnoletto, CEO of Juniper Biosciences, stated in a news release.¹ “The FDA has now recognized that this approach may represent a substantial improvement over the current standard of care. We are very excited to see future patients benefit from it."

About JBS-003 and Clinical Context

Under the current standard of care for HPV-positive OPC, patients receive a uniform, aggressive radiation regimen regardless of individual tumor biology. Although effective, this approach may be accompanied by significant toxicity and long-term effects on quality of life.

JBS-003 is a fluorine-18–labeled form of fluoromisonidazole being developed as a PET imaging agent to detect tumor hypoxia, a recognized marker of radioresistance. The investigational agent is intended to distinguish tumors based on their hypoxic status, allowing radiation treatment to be tailored according to tumor biology.

By using molecular imaging to assess tumor hypoxia, the investigational approach is intended to facilitate risk stratification of patients and identify those with nonhypoxic tumors who may be appropriate for radiation de-escalation, potentially reducing unnecessary radiation exposure and treatment-related toxicity. For patients whose tumors demonstrate hypoxia, the standard-dose treatment would be maintained.

Clinical Development: About the Phase 3 Trial

The designation is supported by evidence from an ongoing randomized, double-blind phase 3 trial (NCT06563479) comparing personalized radiation therapy with JBS-003 vs standard radiation therapy in patients with HPV-positive OPC.² The study aims to evaluate whether the imaging-guided strategy can maintain disease control while reducing radiation exposure in appropriately selected patients, with a primary end point of 2-year overall survival.

In the personalized radiation arm, patients undergo F-MISO PET imaging at week 2 to assess tumor hypoxia. Patients without evidence of hypoxia may receive 30 Gy of radiation, while those with hypoxic tumors continue with the standard 70-Gy dose. Patients receiving standard radiation receive 70 Gy.

The trial is expected to reach primary completion in early 2028.

REFERENCES

1. Juniper’s JBS-003 (F-MISO) Program Receives FDA Breakthrough Therapy Designation, Advancing a First-in-Class Hypoxia Tracer Enabling Radiation De-escalation in HPV-Positive Head and Neck Cancer. News release. Juniper Biosciences. September 1, 2026. Accessed September 2, 2026. https://tinyurl.com/h35sxus3

2. A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer. ClinicalTrials.gov. Updated July 28, 2026. Accessed September 2, 2026. https://clinicaltrials.gov/study/NCT06563479